Системные гипертензии

Расширенный поиск

Доказательная база применения амлодипина при лечении артериальной гипертензии

Об авторах

С. В. Недогода
Волгоградский государственный медицинский университет

У. А. Брель
Волгоградский государственный медицинский университет

Список литературы

1. Hu D, Zhao X, He X et al. Effect of «drug holiday» on blood pressure control; a randomized double-blind comparative trial of amlodipine versus felodipine extended release in Chinese patients with mild to moderate essential hypertension. Heart Drug 2001; 1: 77-82.

2. Чазова И.Е., Бойцов С.А., Небиеридзе Д.В. Основные положения проекта второго пересмотра рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии. Кардиоваскул. тер. и проф. 2004; 4: 90-8.

3. Kloner RA et al. Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol 1996; 77: 713-22.

4. Knight CJ et al. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Am J Cardiol 1998; 81 (2): 133-6.

5. Minami J et al. Effects of amlodipine and nifedipine retard on autonomic nerve activity in hypertensive patients. Clin Exp Pharmacol Physiol 1998; 25 (7-8): 572-6.

6. Van Der Vring JA et al. Combination of calcium channel blockers and b-adrenoreceptor blockers for patients with exercise induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group of Cardiovascular Research (WCN). British J Clin Pharmacol 1999; 47 (5): 493-8.

7. Van Kham et al. Amlodipine versus diltiazem controlled release as monotherapy in patients with stable coronary artery disease. Current Ther Res Clin Exp 1998; 59 (3): 139-48.

8. Zaliunas RZ et al. Effects of amlodipine and lacidipine on heart rate variability in hypertensive patients with stable angina pectoris and isolated left ventricular diastolic dysfunction. International J Cardiology 2005; 101: 347-53.

9. Малышева Е.А., Леонова М.В., Прошин А.Ю., Белоусов Ю.Б. Влияние амлодипина на показатели липидного спектра у больных гипертонической болезнью и атеросклерозом сонных артерий (сообщение 3). Клин. фармакол. и тер. 1998; 7 (1): 2-4.

10. Doggrell SA. Has the controversy over the use of calcium channel blockers in coronary artery disease been resolved? Expert Opin Pharmacother 2005; 6 (5): 831-4.

11. de Champlain J et al. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens 1998; 16 (11): 1357-69.

12. Golgsmith SR. Effect of amlodipine and felodipine on sympathetic activity and baroreflex function in normal humans. Am J Hypertens 1995; 8 (9): 902-8.

13. Deanfield J, Detry JM, Lichtlen PR. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind circadian anti-ischemia program in Europe (CAPE Trial). J Am Coll Cardiol 1994; 24: 1460-7.

14. Detry JM. Amlodipine and the total ischemic burden: Circadian Anti-Ischemia Program in Europe (CAPE) trial - Methodology, safety and toleration. Cardiology 1994; 85 (Suppl. 2): 24-30.

15. Hall RJ. A multicentral study comparing the efficacy and tolerability of nisoldipine coat-core and amlodipine in patients with chronic stable angina. Current Ther Res Clin Exp 1998; 59 (7): 483-97.

16. Petkar S et al. Amlodipine monotherapy in stable angina pectoris. Indian Heart J 1994; 46 (2): 85-8.

17. Rinaldi CA et al. Randomized, double-blind crossover study to investigate the effects of amlodipine and isosorbide mononitrate on the time course and severity of exercise-induced myocardial stunning. Circulation 1998; 98 (8): 749-56.

18. Singh S. Long-tern double-blind evaluation of amlodipine and nadolol in patients with stable exertional angina pectoris. Clin Cardiol 1993; 16 (1): 54-8.

19. Steffensen R et al. Effects of amlodipine and isosorbide dinitrate on exercise-induced and ambulatory ischemia in patients with chronic stable angina pectoris. Cardiovasc Drug Ther 1997; 11 (5): 629-35.

20. Liebson PR, Grandits GA, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91: 698-706.

21. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.

22. Dahlof B, Sever PS, Poulter NR, for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.

23. Pitt B et al. Effect of amlodipine on progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 2000; 102 (13): 1503-10.

24. Pitt B, Byington R, Furberg C et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.

25. Nissen SE, Tuzcu EM, Libby P. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-26.

26. Chahine RA et al. Randomized placebo-controlled trial of amlodipine in vasospastic angina. L Am Coll Cardiol 1993; 21 (6): 1365-70.

27. Packer M, O'Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-14.

28. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes. Principal Results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation. March 7, 2006; 113: 1213-25.

29. Trenkwalder PR, Schaetzl R, Borbas E et al. Efficacy and safety of the combination of amlodipine10/valsartan160 in hypertensive patients not controlled by the combination of ramipril 5/felodipine 5- The ExPress-C. Trial Dtsch med Wochenschr. 2006; 131DOI: 10.1055/s-2006-956640.

30. Stein J. Comparative Safety and Blood Pressure (BP)-Lowering Efficacy of a Combination of Amlodipine (Amlo)+Valsartan and Lisinopril+Hydrochlorothiazide (HCT) in Patients with Stage 2 Hypertension. 21st Annual Scientific Meeting of the American Society of Hypertension, New York. 2006: Abstract P-217.

31. Chrysant SG, Bakris GL. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens 2004; 17: 590-6.

32. Errico M et al. Evaluation of efficacy of amlodipine vs captopril/hydrochlorothiazide in the treatment of essential hypertension. Clin Drug Invest 1997; 13 (Suppl. 1): 102-7.

33. Fogari R, Preti P, Lazzari P et al. Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. Eur J Clin Pharm 2003; 4: 271-5.

34. Fogari R, Preti P, Zoppi A et al. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol 2006; 6: 178-81.

35. Ding YA et al. Comparison of amlodipine and quinapril on ambulatory blood pressure and platelet function in hypertension. J Hum Hypertens 1995; 9 (8): 637-41.

36. Sever PS, Dahlof B, Poulter NP, Wedel H. Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT LLA) revisited: interaction of antihypertensive and lipid lowering therapy. Circulation 2005; 112 (17 Suppl.): II-134. Abstract 730.

37. Sever P on behalf of the ASCOT investigators. ASCOT-LLA revisited: Interaction of antihypertensive and lipid-lowering therapy. American Heart Association Scientific Sessions; November 14, 2005; Dallas, TX.

38. Dorval JF, Anderson T, Buithieu J, Chan S et al. Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease. Am J Cardiol 2005; 95 (2): 249-53.

39. Blank R. A single-pill combination of amlodipine besylate and atorvastatin calcium. Drugs Today (Barc) 2006; 42 (3): 157-75.

40. Jukema JW, van der Hoorn JW. Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. Exp Opin on Pharm 2004; 5: 459-68.

41. Чазова И.Е., Ратова Л.Г. и др. Эффективность антигипертензивной терапии у больных артериальной гипертонией в зависимости от риска сердечно-сосудистых осложнений. Кардиоваск. тер. и проф. 2008; 7 (2): 29-32.

42. Чазова И.Е., Ратова Л.Г. Антагонисты кальция в лечении артериальной гипертонии (исследование ЭТНА). Системн. гипертен. 2005; 1: 25-8.


Для цитирования:

Недогода С.В., Брель У.А. Доказательная база применения амлодипина при лечении артериальной гипертензии. Системные гипертензии. 2008;(2):23-28.

Просмотров: 16

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)